BioInvent International AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioInvent International AB
Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.
Urotronic set to complete a $20m series C, bringing its total funding to $61m for the development of drug-eluting balloon-based urology products.
Merrimack Pharmaceuticals is ending development of its lead drug MM-310 because of safety concerns, triggering a fresh round of job cuts at the troubled Cambridge, Massachusetts-based biotech.
With its focus firmly on oncology, the Swedish biotech, and its outgoing chief, believe the company now needs someone with more scientific skills in the CEO role.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Bioinvent Finans AB